Consensus Arcturus Therapeutics Holdings Inc.

Equities

ARCT

US03969T1097

Market Closed - Nasdaq Other stock markets 04:00:00 2024-05-17 pm EDT			5-day change	1st Jan Change
29.78 ^USD	-2.36%		+9.24%	-5.55%

May. 08	Transcript : Arcturus Therapeutics Holdings Inc., Q1 2024 Earnings Call, May 08, 2024
May. 08	Arcturus Therapeutics Holdings Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024	CI

Evolution of the average Target Price on Arcturus Therapeutics Holdings Inc.

Price target over the last 5 years

History of analyst recommendation changes

11245ceb575332a0d.EEPyZXIZ56kZH0II5fM54Qu3Yh-Ez7Ft4g4ya6NqcgU.WBK2NAJMkewqfRpw1ZJegmyCJVPPnN4yz1pYJeUuBHB2LrE2R2-j-G1qCw~e42975f4f3243de955b93718e014945a

Analyst Recommendations on Arcturus Therapeutics Holdings Inc.

Arcturus Therapeutics Holdings Insider Sold Shares Worth $299,839, According to a Recent SEC Filing	Mar. 21	MT
Canaccord Genuity Adjusts Arcturus Therapeutics Holdings' PT to $87 From $81, Maintains Buy Rating	Mar. 11	MT
Wells Fargo Adjusts Price Target on Arcturus Therapeutics Holdings to $58 From $45, Maintains Overweight Rating	Mar. 08	MT
Citigroup Raises Price Target on Arcturus Therapeutics to $48 From $40, Maintains Buy Rating	Feb. 08	MT
Canaccord Genuity Initiates Arcturus Therapeutics With Buy Rating, $81 Price Target	Dec. 13	MT
William Blair Initiates Arcturus Therapeutics Holdings at Outperform Rating	23-07-24	MT
HC Wainwright Upgrades Arcturus Therapeutics Holdings to Buy From Neutral, Price Target at $51	23-05-11	MT
Goldman Sachs Adjusts Price Target on Arcturus Therapeutics Holdings to $14 From $8, Maintains Sell Rating	22-11-10	MT
Baird Downgrades Arcturus Therapeutics Holdings to Underperform From Neutral, Price Target is $18	22-11-10	MT
Barclays Upgrades Arcturus Therapeutics Holdings to Equalweight From Underweight, Adjusts Price Target to $25 From $16	22-11-02	MT
Arcturus Therapeutics Shares Rise 31% After Vaccine Collaboration	22-11-02	DJ
Cantor Fitzgerald Raises Price Target on Arcturus Therapeutics Holdings to $44 From $39, Keeps Overweight Rating	22-11-02	MT
US Futures Nudge Higher Ahead of Federal Reserve Board Meeting; Fourth Straight Rate Hike Expected	22-11-02	MT
Wells Fargo Adjusts Price Target on Arcturus Therapeutics Holdings to $98 From $105, Reiterates Overweight Rating	22-08-10	MT
Barclays Trims Price Target on Arcturus Therapeutics Holdings to $16 From $17, Reiterates Underweight Rating	22-08-10	MT
Raymond James Downgrades Arcturus Therapeutics Holdings to Underperform From Market Perform	22-08-10	MT
Cantor Fitzgerald Assumes Arcturus Therapeutics Holdings at Overweight, Sets $39 Price Target	22-07-19	MT
Goldman Sachs Adjusts Arcturus Therapeutics Holdings' Price Target to $8 from $14, Keeps Sell Rating	22-05-24	MT
Baird Upgrades Arcturus Therapeutics Holdings to Neutral From Underperform, Cuts Price Target to $18 From $21	22-05-11	MT
Barclays Adjusts Arcturus Therapeutics Holdings' Price Target to $17 from $21, Keeps Underweight Rating	22-05-10	MT
HC Wainwright Lowers Arcturus Therapeutics Holdings Price Target to $19 From $25, Neutral Rating Kept	22-05-10	MT
Citigroup Downgrades Arcturus Therapeutics Holdings to Neutral From Buy; Price Target is $29	22-04-21	MT
Wells Fargo Adjusts Arcturus Therapeutics Holdings' Price Target to $105 from $107, Keeps Overweight Rating	22-03-25	MT
Citigroup Adjusts Price Target on Arcturus Therapeutics Holdings to $86 From $114, Maintains Buy Rating	22-03-15	MT
Barclays Adjusts Price Target on Arcturus Therapeutics Holdings to $21 From $31, Reiterates Underweight Rating	22-03-01	MT

More recommendations

Analysts' Consensus

Sell

Buy

Mean consensus

BUY

Number of Analysts

Last Close Price

29.78 USD

Average target price

72.29 USD

Spread / Average Target

+142.76%

High Price Target

140 USD

Spread / Highest target

+370.11%

Low Price Target

48 USD

Spread / Lowest Target

+61.18%

Consensus detail

Consensus revision (last 18 months)

Analysts covering Arcturus Therapeutics Holdings Inc.

Canaccord Genuity
Wells Fargo Securities
Citigroup
William Blair & Co.
HC Wainwright
Baird
Goldman Sachs
Cantor Fitzgerald
Barclays
Raymond James
Chardan
B. Riley

Ratings for Arcturus Therapeutics Holdings Inc.

Trading Rating

Investor Rating

ESG Refinitiv

D+

More Ratings

EPS Revisions

Estimates Revisions

Quarterly earnings - Rate of surprise

Company calendar